Cited by 106Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 22 of the 41 sources its claims cite were checked for support.

APOE2, E3, and E4 differentially modulate cellular homeostasis, cholesterol metabolism, and inflammatory response in isogenic iPSC-derived astrocytes

Open access

Published version of a preprint

Abstract

The apolipoprotein E4 (APOE4) variant is the strongest genetic risk factor for Alzheimer disease (AD), while the APOE2 allele is protective. A major question is how different APOE genotypes affect the physiology of astrocytes, the main APOE-producing brain cells. Here, we differentiated human APOE-isogenic induced pluripotent stem cells (iPSCs) (APOE4, E3, E2, and APOE knockout [APOE-KO]) to functional "iAstrocytes". Mass-spectrometry-based proteomic analysis showed genotype-dependent reductions of cholesterol and lipid metabolic and biosynthetic pathways (reduction: APOE4 >E3 >E2). Cholesterol efflux and biosynthesis were reduced in APOE4 iAstrocytes, while subcellular localization of cholesterol in lysosomes was elevated. An increase in immunoregulatory proteomic pathways (APOE4 >E3 >E2) was accompanied by elevated cytokine release in APOE4 cells (APOE4 >E3 >E2 >KO). Activation of iAstrocytes exacerbated proteomic changes and cytokine secretion mostly in APOE4 iAstrocytes, while APOE2 and APOE-KO iAstrocytes were least affected. Taken together, APOE4 iAstrocytes reveal a disease-relevant phenotype, causing dysregulated cholesterol/lipid homeostasis, increased inflammatory signaling, and reduced β-amyloid uptake, while APOE2 iAstrocytes show opposing effects.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

APOE-isogenic human iPSC-derived astrocytes show allele-dependent phenotypes, with APOE4 displaying reduced cholesterol/lipid biosynthesis and efflux, increased lysosomal cholesterol, higher inflammatory signaling, and lower glutamate/Aβ42 uptake, while APOE2 often resembles APOE-KO. APOE4 iAstrocytes are also most susceptible to IL-1β-induced proteomic and cytokine changes.

Key findings

  • Differentiation yielded mature, quiescent iAstrocytes from APOE2, APOE3, APOE4, and APOE-KO iPSCs; label-free proteomics detected 3,765 proteins, with 2,432 differentially expressed between NPCs and iAstrocytes (FDR <0.1). APOE-KO samples were omitted from quantitative proteomic analysis because they were more dispersed by PCA and had substantially fewer peptides/proteins.
  • Homeostatic functions declined allele-dependently: glutamate uptake was lowest in APOE4 and highest in APOE2/APOE-KO (KO = E2 > E3 > E4); Aβ42 uptake trended KO > E2 > E3 ≥ E4 (E3 vs E4 p = 0.054), and RAP blocked Aβ uptake in APOE-KO, E2, and E3 but not E4 (p = 0.23).
  • Cholesterol/lipid pathways were downregulated in APOE4 versus E3/E2 by GSEA; FDFT1 and ABCA1 were regulated KO = E2 > E3 > E4; total, cellular, and secreted cholesterol were E2 = E3 > E4 = KO; non-membrane-bound cholesterol was E4 > E3 = E2 = KO; lysosomal cholesterol colocalization was E4 > E2; LAMP2 was E3 > E2 = E4 = KO; lysosomal activity was KO = E2 > E3 = E4.
  • Inflammatory pathways at baseline were E4 > E3 > E2; cytokine release after IL-1β or TNF-α was E4 > E3 > E2 > KO except IL-8, and IL-6/IL-8 were detectable at baseline in APOE4. IL-1β treatment exacerbated proteomic changes mostly in APOE4, while APOE2 and APOE-KO were least affected.

Methods

  • APOE-isogenic iPSC lines from EBiSC (BIONi010-C-2, -C-3, -C-4, -C-6) were differentiated to NPCs and then to iAstrocytes using ScienCell astrocyte medium; FCS was withdrawn and AraC added from day 30–37, with analysis at day 44.
  • Main assays included label-free mass-spectrometry proteomics with GSEA/edgeR, HPTLC lipid quantification, western blot, immunocytochemistry/confocal imaging, flow-cytometry Aβ42 uptake, MSD cytokine measurement, Filipin III/Dextran-Alexa 555 staining, lysosomal activity, and NF-κB assay.
  • Most experiments used three independent experiments with individual data points plotted; MSD cytokine data came from five cell culture wells in one experiment.

Limitations

  • The paper states that APOE-KO iAstrocytes were excluded from quantitative proteomic analysis because of higher variation and lower peptide/protein numbers, which would bias normalization.
  • The paper notes that day 44 iAstrocytes were not susceptible to Aβ42 activation, possibly requiring priming, and that no major endosomal/lysosomal morphology abnormalities were observed; it also cannot exclude a transient NF-κB increase.
  • Evident from the text: each APOE genotype was represented by a single isogenic iPSC line, cytokine data came from one MSD experiment, and findings are from an in vitro iPSC-derived astrocyte model.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.stemcr.2021.11.007

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

22 of 41 cited sources checked · 7 supported · 0 flagged · accuracy not yet measured

Show all 62 claims

  • Probably not a substantial claim. 28
  • It may state two separate claims as one. 77
91 of 91
  • The paper relies on this without support.

    APOE4 is the strongest genetic risk factor for AD, with one allele conferring about a 3-fold increase and two alleles about a 12-fold increase in risk.

    “Carrying the APOE4 allele is the major genetic risk factor for developing sporadic Alzheimer disease (AD), where one allele confers a 3-fold increase and two alleles a 12-fold increase in risk.”
  • The paper relies on this without support.

    The APOE2 allele is protective for AD.

    “The APOE2 allele is protective for AD; however, its biological role is heavily understudied and not yet understood (Michaelson, 2014).”
  • The paper relies on this without support.

    In the brain, APOE is mainly expressed by astrocytes, and in low levels by microglia.

    “In the brain, APOE is one of the most abundant lipoprotein chaperones, mainly expressed by astrocytes, and in low levels by microglia.”
  • The paper relies on this without support.

    Arg158 in APOE4 causes an ionic interaction between Arg61 and Cys255 on the lipid binding domain, leading to altered lipid binding and decreased capacity to load cholesterol.

    “Arg158 in APOE4 causes an ionic interaction between Arg61 and Cys255 on the lipid binding domain, inferring a structural change, leading to altered lipid binding and decreased capacity to load cholesterol.”
  • The paper relies on this without support.

    Aβ42 is mostly taken up through receptor-dependent endocytosis, such as LRP1.

    “Aβ42 is mostly taken up through receptor-dependent endocytosis, such as LRP1.”
  • The paper relies on this without support.

    ABCA1 is essential for lipid and cholesterol efflux, as well as for APOE lipidation.

    “A second protein of interest was ATP-ase binding cassette 1 (ABCA1), essential for lipid and cholesterol efflux, as well as for APOE lipidation.”
  • The paper relies on this without support.

    The four isogenic iPSC lines differ only in APOE genotype and not in other genetic or epigenetic factors that affect the measured phenotypes.

    “iPSC lines were purchased from EBiSC (BIONi010-C-2, -C-3, C-4, and -C-6), harboring a single APOE2, APOE3, or APOE4 allele generated using CRISPR, or an APOE-KO generated by an insertion-deletion mutation in exon 2 (Schmid et al., 2019, 2020).”
  • The paper relies on this without support.

    The in vitro iPSC-derived iAstrocyte model recapitulates relevant aspects of human astrocyte biology and APOE-related AD mechanisms.

    “Our human isogenic mature iAstrocyte cell model represents a powerful tool to further address these open questions.”
  • The paper relies on this without support.

    The APOE-KO iAstrocytes completely lack APOE protein and function.

    “or an APOE-KO generated by an insertion-deletion mutation in exon 2 (Schmid et al., 2019, 2020).”
9 of 9

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Figure 5A caption duplicates a comparison and omits E2 versus E3

    Minor

    The Figure 5A caption lists APOE2 versus APOE4 and the reverse comparison, but no APOE2-versus-APOE3 comparison. The Results cite that figure for the finding that APOE2 is lower than APOE3.

  • Discussion reverses the reported cellular cholesterol ordering

    Minor

    The Results state that cellular cholesterol is lower in APOE4 and APOE-KO than in APOE3. The Discussion instead places APOE4 and APOE-KO above APOE3.

2 of 2

Citations

Cites

Flagged first, then by citations

Show all 42 references

Cited by

Sorted by citations

Items 101–106 of 106

Metadata

Authors
de Leeuw, S. M., Kirschner, A. W. T., Lindner, K., Rust, R., Budny, V., Wolski, W. E., Gavin, A.-C., Nitsch, R. M., & Tackenberg, C.
Affiliations
  • University of Zurich (CH)
  • University of Geneva (CH)
Corresponding author
Tackenberg, Christian
Venue
Stem Cell Reports
Publisher
Elsevier BV
Published
2022-01
Volume
17
Issue
1
Pages
110-126
ISSN
2213-6711 (ISSN-L)
OpenAlex
W4220926198
Cited by
105
References
42
Citations by year
2026: 20 · 2025: 28 · 2024: 25 · 2023: 20 · 2022: 12
FWCI
8.95
Type
journal article
Language
en
Update notices
erratum (2022-05-10)
Open access
Locations
  • Stem Cell Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Universität Zürich
  • Neuroscience Center Zurich, University of Zurich
  • Louis-Jeantet Foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
apolipoprotein E, APOE ε4, APOE2, APOE3, apolipoprotein E deficiency, astrocytes, induced pluripotent stem cell-derived astrocytes, isogenic iPSC lines, cholesterol metabolism, lipid metabolism, lysosomal cholesterol, cytokine production, neuroinflammation, Alzheimer's disease risk, proteomic profiling
MeSH terms
Alleles, Astrocytes, Cell Cycle, Cell Differentiation, Cholesterol, Genotype, Homeostasis, Humans, Immunohistochemistry, Inflammation, Lipid Metabolism, Apolipoprotein E3, Apolipoprotein E4, Apolipoprotein E2, Induced Pluripotent Stem Cells, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-31, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-31 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review